Gilead Sciences, Inc. (NASDAQ:GILD) announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi(R) (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus (HCV) infection in patients with advanced liver disease. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -7.32% in last session and finished the day at $65.48. Traded volume was 43.15million shares in the last session and the average volume of the stock remained 14.39million shares. The beta of the stock remained 0.58. Gilead Sciences, Inc. (NASDAQ:GILD) insider ownership is 0.50%.

In 2004, Pfizer Inc. (NYSE:PFE), which purchased licensing rights for Depo Provera from Phramacia & Upjohn Inc., submitted information to the FDA stating that women who receive the Depo Provera injection experience significant loss of bone mineral density. The FDA responded by giving Depo Provera a “Black Box Warning” meaning all possible side effects would have to be discussed with any person receiving the drug. Pfizer Inc. (NYSE:PFE) dropped -1.99 percent to $30.61 Thursday on volume of 30.44million shares. The intra-day range of the stock was $30.51 to $31.43. Pfizer Inc. (NYSE:PFE) has a market capitalization of $195.71billion.

Merck & Co., Inc. (NYSE:MRK), known as MSD outside of the United States and Canada, today announced interim results from the ongoing C-WORTHy study, a multi-arm Phase 2 clinical trial evaluating the efficacy and safety of an all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, among patients with chronic HCV Genotype 1 infection (GT1). Merck & Co., Inc. (NYSE:MRK)’s stock on Apr 10, 2014 reported a decrease of -2.19% to the closing price of $55.85. Its fifty two weeks range is $44.60 -$58.14. The total market capitalization recorded $164.23billion. The overall volume in the last trading session was 18.03million shares. In its share capital, MRK has 2.94billion outstanding shares.

MannKind Corporation (MNKD:NASDAQ), with its inhalable insulin product Afrezza (human insulin of recombinant DNA origin delivered via Technosphere particles). It had an AdCom meeting on April 1 and the PDUFA date is now set at July 15. On Thursday, shares of MannKind Corporation (NASDAQ:MNKD) dropped -2.14% to close the day at $6.85. Company monthly performance is recorded as 20.39%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is -3.25%.